Sitagliptin Use and its Continuous Glycemic Control Effcets in Japanese patients with type 2 diabetes in Saitama

Sitagliptin Use and its Continuous Glycemic Control Effcets in Japanese patients with type 2 diabetes in Saitama - SUCCEED trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005076

Enrollment

400

Registered

2011-02-14

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Duration: 104 weeks Therapy: Sitagliptin 50 mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with the ages of more than 20 years. 2. Patients who do not recieve any anti-diabetic agent within 1 month. 3. HbA1c levels (JDS values) ranging from 6.5 to 7.9 % at baseline. 4. Both outpatients and inpatients

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 diabetes 2. Renal impairment (Serum creatinine more than 1.5 mg/dl in men or 1.3 mg/dl in women) 4. Patients who undergo surgery 5. Preganat women

Design outcomes

Primary

Measure	Time frame
1. To achieve HbA1c less than 7.0% (JDS values) at 12 weeks after treatment with sitagliptin 2. The time to monotherapy failure	—

Countries

Japan

Contacts

Public ContactKozo Takebayashi

Dokkyo Medical University, Internal Medicine

takebaya@dokkyomed.ac.jp048-965-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026